AG真人官方

Plus Therapeutics reported the results of its August 7, 2025 annual meeting. Of 60,490,101 shares outstanding at the June 18, 2025 record date, 29,973,272 shares were represented, constituting a quorum. All director nominees listed in the proxy were elected, with individual "for" votes generally in the range of 18.7 million to 18.94 million and 10,294,600 broker non-votes recorded for those director elections.

Stockholders approved several material proposals: authorization to potentially issue up to $50.0 million of common stock (plus up to $1.0 million as a commitment fee) to Lincoln Park Capital under the June 17, 2025 purchase agreement; discretionary authority for the board to effect a reverse stock split at any ratio between 1-for-2 and 1-for-250; an advisory approval of named executive officer compensation; and the fifth amendment and restatement of the 2020 Stock Incentive Plan.

Plus Therapeutics (PSTV) filed a registration statement to register up to 33,000,000 shares for resale by Lincoln Park Capital Fund under a purchase agreement that can provide up to $50.0 million of aggregate gross proceeds (an initial $25.0 million available amount with an automatic additional $25.0 million upon satisfaction of conditions). The company has received approximately $2.8 million to date and intends to issue 1,612,903 Initial Commitment Shares valued at $0.31 as part of the commitment fee. The filing shows 99,264,526 shares outstanding and a pro forma 132,264,526 if all registered shares are issued, and highlights potential dilution, dependence on Lincoln Park as a financing source, a disclosed Make-Whole Repayment obligation of approximately $17.3 million, and that any proceeds would be used for working capital, general corporate purposes and, if required, repayment obligations.

Schedule 13G/A (Amendment No. 1) filing for Plus Therapeutics, Inc. (NASDAQ: PSTV) discloses that The Hewlett Fund LP no longer holds any beneficial ownership in the company鈥檚 common stock.

Key facts:

• Date of event: 24 June 2025
• Reporting person: The Hewlett Fund LP (a New York limited partnership)
• Shares beneficially owned: 0.00
• Percent of class: 0%
• Voting & dispositive power: 0 shares sole or shared
• Reason for filing: Ownership has fallen to (or remains) 5 percent or less of outstanding common stock, triggering a final amendment under Rule 13d-2.

This amendment replaces an earlier Schedule 13G in which the same fund reported an ownership position exceeding the 5 % reporting threshold. By certifying zero shares, The Hewlett Fund LP confirms that it has fully exited its previously disclosed stake and no longer seeks to influence control of Plus Therapeutics. Apart from this ownership update, the filing contains no financial performance data, strategic commentary or transactional details.

The Securities and Exchange Commission has declared Plus Therapeutics' Form S-1 registration statement effective as of June 23, 2025, at 9:00 A.M. The registration statement was filed under File Number 333-288121.

A Form S-1 is a crucial SEC filing used for registering new securities offerings with the SEC. This effectiveness notice indicates that Plus Therapeutics has completed the registration process and received regulatory approval to proceed with their planned securities offering.

This development is significant for investors as it typically precedes:

• A new public offering of securities
• The ability to begin selling registered securities to the public
• Potential changes in the company's capital structure